Recently revumenib, a first in class oral menin inhibitor was approved for patients >1 year of age with relapsed or refractory (R/R) KMT2A-r acute leukemias (AML, ALL or mixed phenotypic acute leukemia [MPAL]). Here, MEN1 is linked to acute myeloid leukemia.